18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
18:35 , May 15, 2018 |  BC Innovations  |  Translation in Brief

Sustained delivery

Researchers from Vanderbilt University School of Medicine and Baylor College of Medicine have developed a new method for stable, long-term delivery of therapeutic proteins using antigen-specific T cells whose genomes have been modified with a...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
23:23 , May 4, 2018 |  BC Extra  |  Preclinical News

PPAR agonist-induced fatty acid metabolism boosts tissue regeneration

Scientists at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology published a paper in Cell Stem Cell showing that fatty acid oxidation (FAO) induced by short-term fasting promotes tissue regeneration and repair,...
01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
21:14 , Dec 14, 2017 |  BC Innovations  |  Emerging Company Profile

Backpacks for CARs

Torque Therapeutics Inc. is making “backpacks” for immune cell therapies that release immune stimulatory molecules at particular doses and locations to boost the cells’ activity without risking systemic exposure. The technology could augment the success...
01:29 , Nov 29, 2017 |  BC Extra  |  Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology, researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the pathway...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...